AstraZeneca (NASDAQ:AZN) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

AstraZeneca (NASDAQ:AZN) issued its quarterly earnings data on Tuesday. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03, Zacks reports. The business had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.41% and a net margin of 12.68%. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.87 EPS.

AstraZeneca Stock Performance

AstraZeneca stock traded up $0.37 on Thursday, hitting $65.66. The company’s stock had a trading volume of 4,605,378 shares, compared to its average volume of 5,241,052. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The company has a fifty day moving average price of $75.79 and a 200-day moving average price of $78.38. AstraZeneca has a one year low of $60.47 and a one year high of $87.68. The firm has a market cap of $203.58 billion, a P/E ratio of 31.24, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. TD Cowen lifted their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.